[go: up one dir, main page]

MX2013004817A - Enfermedad inflamatoria. - Google Patents

Enfermedad inflamatoria.

Info

Publication number
MX2013004817A
MX2013004817A MX2013004817A MX2013004817A MX2013004817A MX 2013004817 A MX2013004817 A MX 2013004817A MX 2013004817 A MX2013004817 A MX 2013004817A MX 2013004817 A MX2013004817 A MX 2013004817A MX 2013004817 A MX2013004817 A MX 2013004817A
Authority
MX
Mexico
Prior art keywords
treatment
inflammatory diseases
compositions
inflammatory disease
adjuvant
Prior art date
Application number
MX2013004817A
Other languages
English (en)
Inventor
Robin Mark Bannister
John Brew
Gregory Alan Stoloff
Wilson Capaross-Wanderley
Olga Pleguezuelos Mateo
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of MX2013004817A publication Critical patent/MX2013004817A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)

Abstract

La presente invención se refiere a al tratamiento de enfermedades inflamatorias, y especialmente Enfermedades inflamatorias mediadas por Th-1. En particular, la invención se refiere al tratamiento de enfermedades inflamatorias mediadas por Th-1 usando un rango de composiciones, y al uso de estas composiciones en métodos de tratamiento. La invención se extiende a adyuvantes, para uso en el tratamiento de una amplia variedad de condiciones médicas. La invención también proporciona composiciones farmacéuticas y medicamentos que comprenden el adyuvante, y a usos del adyuvante en métodos de tratamiento y para provocar una respuesta inmune.
MX2013004817A 2010-10-29 2011-10-31 Enfermedad inflamatoria. MX2013004817A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1018289.7A GB201018289D0 (en) 2010-10-29 2010-10-29 Treatment of respiratory disorders
GB1113728.8A GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol
PCT/GB2011/052115 WO2012056251A1 (en) 2010-10-29 2011-10-31 Inflammatory disease

Publications (1)

Publication Number Publication Date
MX2013004817A true MX2013004817A (es) 2013-07-03

Family

ID=43401508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004817A MX2013004817A (es) 2010-10-29 2011-10-31 Enfermedad inflamatoria.

Country Status (11)

Country Link
EP (1) EP2632431A1 (es)
JP (1) JP2013544802A (es)
CN (1) CN103282021A (es)
AU (1) AU2011322255A1 (es)
BR (1) BR112013010441A2 (es)
CA (1) CA2816564A1 (es)
GB (2) GB201018289D0 (es)
MX (1) MX2013004817A (es)
RU (1) RU2013124514A (es)
SG (1) SG189551A1 (es)
WO (1) WO2012056251A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CN103391768B (zh) 2011-02-04 2016-08-10 第一医疗保健有限公司 治疗慢性炎症和炎性疾病的组合物和方法
JP2014040396A (ja) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute 脂質異常症治療薬を含有するアジュバント組成物
CN104098686B (zh) * 2013-04-03 2016-03-23 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN103880924B (zh) * 2012-12-21 2016-03-23 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN103880941B (zh) * 2012-12-21 2016-02-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
BR112015015858B1 (pt) * 2013-01-14 2023-02-28 Infirst Healthcare Limited Uso de uma composição farmacêutica de solução sólida no tratamento de uma inflamação crônica
CN104098671A (zh) * 2013-04-03 2014-10-15 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN104098685B (zh) * 2013-04-03 2016-03-23 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN104098681B (zh) * 2013-04-03 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
US9943568B2 (en) * 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
US10098864B2 (en) * 2013-08-19 2018-10-16 Enzychem Lifesciences Corporation Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
CN105530930A (zh) * 2013-08-19 2016-04-27 Enzychem生命科学株式会社 含有以单乙酰基二酰基甘油化合物作为有效成分的类风湿性关节炎的预防或者治疗用组合物
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN103932977A (zh) * 2014-04-15 2014-07-23 江苏正大清江制药有限公司 一种塞来昔布制剂的制备方法
CN103893171B (zh) * 2014-04-19 2016-05-25 武汉胜达康生物科技有限公司 盐酸苄达明在制备治疗或预防流感病毒感染药物中的应用
JP6893012B2 (ja) * 2017-07-18 2021-06-23 徳義制薬有限公司Ｄｅｙｉ Ｐｈａｒｍａｒｍａｃｅｕｔｉｃａｌ Ｌｔｄ． 肺高血圧症の治療におけるカンナビジオールの応用
US11452707B2 (en) * 2017-08-31 2022-09-27 Hanyi Bio-Technology (Beijing) Co., Ltd. Use of cannabidiol in preparation of drugs for resisting against influenza
CN109419786B (zh) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 大麻二酚在制备抗流感的药物中的用途
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US12520867B2 (en) 2019-12-09 2026-01-13 Nicoventures Trading Limited Buffered oral compositions
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG
CN111214467A (zh) * 2020-03-05 2020-06-02 南京巴傲得生物科技有限公司 吲哚布洛芬在抵抗hmgb1促炎活性中的应用
CN111281973A (zh) * 2020-03-31 2020-06-16 清华大学 含有trpv2激动剂的疫苗佐剂及其用途
CA3223902A1 (en) 2021-06-25 2022-12-29 Richard Svensson Oral products and method of manufacture
KR20230050232A (ko) * 2021-10-07 2023-04-14 주식회사 이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
EP0724452B1 (de) * 1993-10-22 2000-05-24 Hexal Ag Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
WO2008051186A2 (en) * 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
US20100125060A1 (en) * 2008-11-19 2010-05-20 Majid Razzak Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
CN103391768B (zh) * 2011-02-04 2016-08-10 第一医疗保健有限公司 治疗慢性炎症和炎性疾病的组合物和方法

Also Published As

Publication number Publication date
CN103282021A (zh) 2013-09-04
EP2632431A1 (en) 2013-09-04
BR112013010441A2 (pt) 2016-08-09
SG189551A1 (en) 2013-06-28
GB201018289D0 (en) 2010-12-15
JP2013544802A (ja) 2013-12-19
GB201113728D0 (en) 2011-09-21
AU2011322255A1 (en) 2013-05-23
GB2487808A (en) 2012-08-08
WO2012056251A1 (en) 2012-05-03
CA2816564A1 (en) 2012-05-03
RU2013124514A (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
MX2013004817A (es) Enfermedad inflamatoria.
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
IL227990B (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione for preparation of medicaments for treatment of immune-related and inflammatory diseases
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
JOP20130236B1 (ar) تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha
MX362485B (es) Nuevos inhibidores de rock.
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
LT4104824T (lt) Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
CY1118402T1 (el) Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
IN2014DN09240A (es)